ELX-02 is in the early stages of clinical development focusing ... and the quotation of the Company’s common stock on …
KTVN14d
Following the reverse stock split and post-acquisition ... Eloxx’s lead product candidate, ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. Eloxx was founded in 2013 and maintains offices in …
Wesfarmers Limited (ASX:WES) and Baby Bunting Group Ltd (ASX:BBN) are among December's top stock picks.
"I believe Eloxx has tremendous potential and I look forward to the continued advancement of ELX-02 across a wide …
Emulex Corp. (ELX) is expected to report results for the fourth quarter ... The shares closed Wednesday at $6.90. (The stock declined nearly 31% in Q4; MA(50)- $6.75; MA(100)- $7.84; 52-wk H/L $11.19/$5.85) Movie and television studio …
The stock entered the trading halt after rising 46 cents, or 18.5 per cent, to $2.95 this morning, reaching their highest level since September 4. Austal said the trading halt was necessary pending a release regarding the Littoral Combat Ship …
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an …
Under the terms of the agreement, Eloxx shareholders will receive shares of Sevion’s common stock reflecting 70% of Sevion’s share ... Eloxx's lead compound, ELX-02, provides unique opportunity to potentially be the first disease …